Filing Flows › Glaukos (GKOS) › Q3 2026 › vs Q3 2025
Glaukos (GKOS) Q3 2026 vs Q3 2025 (year over year)
Glaukos's revenue rose $77.5M (+58%) from $134M in Q3 2025 to $211M in Q3 2026. The biggest changes: Glaucoma +$41.7M (+38%); Corneal Health +$35.8M (+154%). Gross margin 85.2% against 78.4% (+6.8 pts).
Glaukos, Q3 2026: revenue $211M (+58% year over year), operating margin 0.4%, net earnings $2.0M, operating cash flow $38.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 85.2% | 78.4% | +6.8 pts |
| Operating margin | 0.4% | -12.3% | +12.6 pts |
| Net margin | 1.0% | -12.2% | +13.1 pts |
| Free cash flow margin | 17.3% | -8.8% | +26.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Glaucoma | $152M | $110M | $41.7M | +38% |
| Corneal Health | $59.0M | $23.3M | $35.8M | +154% |
| Revenue | $211M | $134M | $77.5M | +58% |
| Gross profit | $180M | $105M | $75.2M | +72% |
| Cost of revenue | $31.2M | $28.8M | $2.3M | +8% |
| Other income, net | $1.5M | $368K | $1.1M | +306% |
| Operating profit | $828K | −$16.4M | $17.2M | — |
| Operating expenses | $179M | $121M | $58.0M | +48% |
| Pre-tax earnings | $2.3M | −$16.0M | $18.3M | — |
| Research & development | $31.0M | $26.9M | $4.1M | +15% |
| Sales & marketing | $55.2M | $40.2M | $15.0M | +37% |
| General & admin | $75.7M | $42.8M | $32.9M | +77% |
| Other operating costs | $17.1M | $11.2M | $5.9M | +53% |
| Net earnings | $2.0M | −$16.2M | $18.2M | — |
| Income tax | $303K | $234K | $69K | +29% |
| Depreciation & amortization | $9.0M | $9.1M | −$180K | -2% |
| Share-based compensation | $17.8M | $14.9M | $2.9M | +19% |
| Working capital & other | $9.8M | −$17.9M | $27.7M | — |
| Operating cash flow | $38.6M | −$10.1M | $48.7M | — |
| Free cash flow (OCF − capex) | $36.5M | −$11.7M | $48.2M | — |
| Capital expenditures | $2.1M | $1.6M | $444K | +27% |
Questions
How much did Glaukos's revenue grow year over year in Q3 2026?
Glaukos's revenue rose $77.5M (+58%) from $134M in Q3 2025 to $211M in Q3 2026.
What drove Glaukos's revenue change in Q3 2026?
Glaucoma +$41.7M (+38%); Corneal Health +$35.8M (+154%).